Literature DB >> 17848631

Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice.

Shiguang Liu1, Wen Tang, Jianping Zhou, Luke Vierthaler, L Darryl Quarles.   

Abstract

X-linked hypophosphatemia (XLH) is characterized by hypophosphatemia and impaired mineralization caused by mutations of the PHEX endopeptidase (phosphate-regulating gene with homologies to endopeptidases on the X chromosome), which leads to the overproduction of the phosphaturic fibroblast growth factor 23 (FGF23) in osteocytes. The mechanism whereby PHEX mutations increase FGF23 expression and impair mineralization is uncertain. Either an intrinsic osteocyte abnormality or unidentified PHEX substrates could stimulate FGF23 in XLH. Similarly, impaired mineralization in XLH could result solely from hypophosphatemia or from a concomitant PHEX-dependent intrinsic osteocyte abnormality. To distinguish between these possibilities, we assessed FGF23 expression and mineralization after reciprocal bone cross-transplantations between wild-type (WT) mice and the Hyp mouse model of XLH. We found that increased FGF23 expression in Hyp bone results from a local effect of PHEX deficiency, since FGF23 was increased in Hyp osteocytes before and after explantation into WT mice but was not increased in WT osteocytes after explantation into Hyp mice. WT bone explanted into Hyp mice developed rickets and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization. Unexpectedly, we observed a paradoxical suppression of FGF23 in juvenile Hyp bone explanted into adult Hyp mice, indicating the presence of an age-dependent systemic inhibitor of FGF23. Thus PHEX functions in bone to coordinate bone mineralization and systemic phosphate homeostasis by directly regulating the mineralization process and producing FGF23. In addition, systemic counterregulatory factors that attenuate the upregulation of FGF23 expression in Hyp mouse osteocytes are present in older mice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17848631     DOI: 10.1152/ajpendo.00396.2007

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  48 in total

Review 1.  Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism.

Authors:  L Darryl Quarles
Journal:  Nat Rev Endocrinol       Date:  2012-01-17       Impact factor: 43.330

2.  Ablation of systemic phosphate-regulating gene fibroblast growth factor 23 (Fgf23) compromises the dentoalveolar complex.

Authors:  E Y Chu; H Fong; F A Blethen; K A Tompkins; B L Foster; K D Yeh; K J Nagatomo; D Matsa-Dunn; D Sitara; B Lanske; R B Rutherford; M J Somerman
Journal:  Anat Rec (Hoboken)       Date:  2010-07       Impact factor: 2.064

Review 3.  Tertiary excess of fibroblast growth factor 23 and hypophosphatemia following kidney transplantation.

Authors:  Wacharee Seeherunvong; Myles Wolf
Journal:  Pediatr Transplant       Date:  2010-10-08

4.  1,25-Dihydroxyvitamin D Alone Improves Skeletal Growth, Microarchitecture, and Strength in a Murine Model of XLH, Despite Enhanced FGF23 Expression.

Authors:  Eva S Liu; Janaina S Martins; Adalbert Raimann; Byongsoo Timothy Chae; Daniel J Brooks; Vanda Jorgetti; Mary L Bouxsein; Marie B Demay
Journal:  J Bone Miner Res       Date:  2016-02-02       Impact factor: 6.741

Review 5.  Endocrine functions of bone in mineral metabolism regulation.

Authors:  L Darryl Quarles
Journal:  J Clin Invest       Date:  2008-12-01       Impact factor: 14.808

Review 6.  Heritable and acquired disorders of phosphate metabolism: Etiologies involving FGF23 and current therapeutics.

Authors:  Erica L Clinkenbeard; Kenneth E White
Journal:  Bone       Date:  2017-01-31       Impact factor: 4.398

7.  Letter to the Editor: "Increased Circulating FGF23 Does Not Lead to Cardiac Hypertrophy in the Male Hyp Mouse Model of XLH".

Authors:  Xiaobin Han; L Darryl Quarles
Journal:  Endocrinology       Date:  2018-11-01       Impact factor: 4.736

Review 8.  Post-renal transplantation hypophosphatemia.

Authors:  Khashayar Sakhaee
Journal:  Pediatr Nephrol       Date:  2009-07-15       Impact factor: 3.714

9.  Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis.

Authors:  Katherine Wesseling-Perry; Renata C Pereira; Hejing Wang; Robert M Elashoff; Shobha Sahney; Barbara Gales; Harald Jüppner; Isidro B Salusky
Journal:  J Clin Endocrinol Metab       Date:  2008-12-02       Impact factor: 5.958

Review 10.  FGF-23 in bone biology.

Authors:  Katherine Wesseling-Perry
Journal:  Pediatr Nephrol       Date:  2009-12-15       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.